And Novo Nordisk (NYSE: NVO) stock, down 4.9%, is the victim. Where to invest $1,000 right now? Our analyst team just ...

The new center will be a hub for both Roche and Genentech, bringing together expertise in Cardiovascular, Renal, and Metabolism, as well as for data science and AI specialists to drive innovation ...

Roche Touts Food Allergy Drug As Superior Than ... an oligopoly ruled by two pharmaceutical giants, Novo Nordisk A/S (NYSE:NVO), maker of semaglutide under the Ozempic and Wegovy name ...

Pfizer (NYSE:PFE) has decided to end R&D and marketing activities related to Beqvez, a one-time gene therapy the company has developed with Roche’s (OTCQX:RHHBY) (OTCQX:RHHBF) Spark Therapeutics ...

Investing.com -- Novo Nordisk (CSE:NOVOb) (NYSE:NVO) shares slumped Wednesday after Roche (SIX:ROG) struck a $5.3 billion deal to acquire rights to an obesity treatment from Denmark’s Zealand ...

Sources: FactSet, Dow Jones Stock Movers: Gainers, decliners and most actives market activity tables are a combination of NYSE, Nasdaq, NYSE American and NYSE Arca listings. Sources: FactSet ...

Roche Holding AG (OTC:RHHBY) reportedly turned down a potential blockbuster weight-loss pill in 2018, allowing Eli Lilly And Co (NYSE:LLY) to acquire the drug, now known as orforglipron ...

Novo Nordisk owns two of them: Ozempic and Wegovy. Eli Lilly (NYSE: LLY) owns the other two: Mounjaro and Zepbound. Both Viking and Roche are attempting to horn in on this market, however.

Roche is meanwhile tying up with Denmark's Zealand Pharma to invent a better GLP-1 weigh-loss drug. Despite these developments, Novo Nordisk stock remains the most attractively valued GLP-1 ...